Search Results

CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season - Jul 17, 2023

https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season

The results demonstrate that the A(H5N1) sa-mRNA influenza vaccine candidate induced an anti-HA and anti-NA neutralizing response raised by sa-mRNA influenza vaccines at a dose as low as 0.01 μg in mice and also induced HA-specific CD4+ T cells.

https://newsroom.csl.com/2022-10-05-CSL-Announces-Positive-Preclinical-Data-for-Self-Amplifying-Messenger-RNA-sa-mRNA-Influenza-Vaccine-Candidates

CSL Seqirus is a global influenza vaccine provider developing innovative solutions.

https://www.csl.com/patients-public-health/vaccines

In Belgium, where roughly 62% of older adults received a standard-dose egg-based influenza vaccine between 2015-2019, an analysis was conducted to investigate the potential cost effectiveness of using an adjuvanted quadrivalent influenza vaccine (aQIV).

https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources

Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine vs High-Dose Influenza Vaccine in Older Adults with Influenza Risk Factors during the 2019-2020 U.S. Influenza Season.

https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health

CSL Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing/csl-seqirus-manufacturing-technologies

With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics

CSL Seqirus has been an active and reliable partner to the UK across pandemic influenza vaccines for many years."

https://newsroom.csl.com/2023-09-26-CSL-Seqirus-secures-multi-year-pandemic-preparedness-agreement-as-part-of-its-continued-partnership-with-the-UK-government

CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.

https://www.csl.com/research-and-development/product-pipeline

Understand our aim to develop the next generation of influenza vaccines and how we're working to unite product platforms across the globe.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing/csl-seqirus-manufacturing-technical-development